Published 13th October 2017

Inivata collaborates with Genomics England to assess samples and explore potential of liquid biopsy to improve cancer management and patient outcomes

Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, has announced that it is collaborating with Genomics England to assess the quality of blood plasma samples and explore the potential of liquid biopsy to improve disease management and patient outcomes.

In the first phase of a larger pilot, Inivata will analyse plasma samples donated by participants in Genomics England’s 100,000 Genomes Project. As well as determining the suitability of plasma, the study will focus on the use of Inivata’s world-leading liquid biopsy technology, InVision, to discover the mutations in the human genome that can lead to or demonstrate the presence of cancer.

These results, and those from the two subsequent phases, will be shared with researchers in the UK and around the world − with the potential to develop less invasive sample collection techniques, more effective monitoring processes and, ultimately, better cancer care.

Read Inivata's statement

Press contacts